Evaluated in 4 short-term and 1 longer-term placebo-controlled trials
Compared vs 7 commonly prescribed oral antipsychotics
Compared vs 6 oral antipsychotics in recently diagnosed (within 1-5 years) adults
A post hoc analysis evaluated the risk of relapse in adult patients based on time since diagnosis (ranging from 0-5 years)
Hospital Readmissions Analysis
Evaluated rehospitalization rates vs oral antipsychotics
TRUST WHAT YOU KNOW
INVEGA SUSTENNA® has a proven efficacy and safety profile, prescribed by mental health providers for >15 years1–3,5,6
References: 1. INVEGA SUSTENNA® [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. 2. Alphs L, Benson C, Cheshire-Kinney K, et al. Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board–blinded 15-month study. J Clin Psychiatry. 2015;76(5):554-561. 3. Schreiner A, Aadamsoo K, Altamura AC, et al. Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia. Schizophr Res. 2015;169(1-3):393-399. 4. Pilon D, Amos TB, Kamstra R, Manceur AM, El Khoury AC, Lefebvre P. Short-term rehospitalizations in young adults with schizophrenia treated with once-monthly paliperidone palmitate or oral atypical antipsychotics: a retrospective analysis. Curr Med Res Opin. 2019;35(1):41-49. 5. Sajatovic M, Doring M, Lopena OJ, et al. Earlier use of long-acting injectable paliperidone palmitate once-monthly vs oral antipsychotics in patients with schizophrenia: an integrated patient-level meta analysis of the PROSIPAL and PRIDE studies. Neuropsychiatr Dis Treat. 2024;20:2227-2235. 6. Center for Drug Evaluation and Research. Approval letter. July 31, 2009. Accessed December 18, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022264s000Approv.pdf